# FIGHT-101 (NCT02393248)

> Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

No report yet. It can be ordered.

- Drugs tested: pemigatinib
- Indication: advanced malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02393248
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Incyte Corporation
- Conditions: Lung Cancer; Solid Tumor; Gastric Cancer; Urothelial Cancer; Endometrial Cancer; Multiple Myeloma; Myeloproliferative Neoplasms; Breast Cancer; Cholangiocarcinoma; UC; MPN
- Interventions: Pemigatinib; Gemcitabine; Pembrolizumab; Docetaxel; Trastuzumab; Retifanlimab; Cisplatin
- Enrollment: 201
- Primary outcome: Parts 1 and 2 Combined: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
- Primary outcome: Part 3: Number of Participants With Any TEAE
- Primary outcome: E0 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Primary outcome: EC50 Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Primary outcome: Emax Following Once Daily Dosing of Pemigatinib as Monotherapy in Parts 1 and 2
- Primary outcome: Highest Serum Phosphate Concentration Following Pemigatinib as Monotherapy in Parts 1 and 2

## Indexed commentary on FIGHT-101 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 11

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=fight-101-nct02393248

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02393248", "email": "<work email>"}; the inbox owner confirms by the emailed link.